Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 8629: Developing the Community Health Workforce Act of 2026”

Referred to the House Committee on Foreign Affairs.

Original title: “HR 8582: Protecting Human Rights and Public Health in Foreign Assistance Act”

Read twice and referred to the Committee on Environment and Public Works.

Original title: “S 4451: Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026”

Read twice and referred to the Committee on Foreign Relations.

Original title: “S 4436: Protecting Human Rights and Public Health in Foreign Assistance Act”

The Food and Drug Administration (FDA) is classifying the external condom for anal intercourse or vaginal intercourse into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the external condom for anal intercourse or vaginal intercourse. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safet

Original title: “Medical Devices; Obstetrical and Gynecological Devices; Classification of the External Condom for Anal Intercourse or Vaginal Intercourse”

The Food and Drug Administration (FDA or Agency) has determined that leucovorin calcium, oral solution, equivalent to (EQ) 60 milligrams (mg) base/vial, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for leucovorin calcium, oral solution, EQ 60 mg, if all other legal and regulatory requirements are met.

Original title: “Determination That Leucovorin Calcium, Oral Solution, Equivalent to 60 Milligrams Base/Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness”

Placed on the Union Calendar, Calendar No. 254.

Original title: “HR 4273: Over-the-Counter Monograph Drug User Fee Amendments”

Placed on Senate Legislative Calendar under General Orders. Calendar No. 152.

Original title: “S 2292: Over-the-Counter Monograph Drug User Fee Amendments”

Implemented as part of a broader initiative to make more targeted and efficient use of inspection resources, the pilot program will use artificial intelligence to enable shorter, focused screenings to complement standard FDA inspections.

Original title: “FDA pilots AI-informed one-day facility inspections”

Acting Center for Drug Evaluation and Research Director Tracy Beth Høeg reportedly disagreed with staff who wanted to approve Sanofi’s type 1 diabetes drug. It’s far from the first time a political appointee has allegedly meddled in a recent FDA decision.

Original title: “Sanofi requests removal of Tzield from CNPV program after Høeg gets involved”

Referred to the House Committee on Science, Space, and Technology.

Original title: “HR 8530: Quantum for Health Act”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 8487: Ensuring Excellence in Mental Health Act”

Referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S2175)

Original title: “SRES 710: A resolution recognizing Maternal Mental Health Day to raise awareness about maternal mental health.”

The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.

Original title: “3 top FDA, CDC roles filled by 15 different people in less than 18 months”

HRSA published a 30-day public notice in the Federal Register on February 3, 2026, (Federal Register volume 91, number 22, pp. 4927- 4931) soliciting feedback on updated criteria for determining maternity care target areas (MCTA). In particular, HRSA requested feedback on proposed changes to the criteria and point scales for MCTAs by removing the criterion for Social Vulnerability Index (SVI) and reallocating its two points as follows: one point to population-to-full-time equivalent maternity ca

Original title: “Notice of Criteria for Determining Maternity Care Health Professional Target Areas”

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Patient-Matched Guides for Orthopedic Implants." This guidance document provides recommendations regarding information that should be included in regulatory submissions for patient-matched guides for orthopedic implants. This guidance also provides recommendations that manufacturers should consider when developing their design process for these device types. This guidance is intended to pr

Original title: “Patient-Matched Guides for Orthopedic Implants; Guidance for Industry and Food and Drug Administration Staff; Availability”

The Food and Drug Administration (FDA, Agency, or we) has determined that MICARDIS (telmisartan), tablets, 20 milligrams (mg) and 80 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to these products as long as they meet relevant legal and regulatory re

Original title: “Determination That MICARDIS (Telmisartan), Tablets, 20 Milligrams and 80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness”

The Food and Drug Administration (FDA) is announcing the renewal of the Blood Products Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Blood Products Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the May 13, 2028, expiration date.

Original title: “Advisory Committee; Blood Products Advisory Committee; Renewal”

The Office on Trafficking in Persons (OTIP), Administration for Children and Families (ACF), U.S. Department of Health and Human Services, is requesting an extension of approval with revisions of an Office of Management and Budget (OMB) approved information collection: National Human Trafficking Training and Technical Assistance Center (NHTTAC) Evaluation Package (OMB #: 0970-0519; expiration date June 30, 2026).

Original title: “Proposed Information Collection Activity; National Human Trafficking Training and Technical Assistance Center Evaluation Package”